Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.35 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29122007 | 0.88 | CNR1 (0.41) | CNR1CNR2ROCK1ROCK2MAPT | |
| SCHEMBL19997295 | 0.87 | ROCK1 (0.42) | CNR1CNR2ROCK1ROCK2TDO2 | |
| SCHEMBL30676470 | 0.80 | ELANE (0.48) | CNR1CNR2ROCK1ROCK2SLC2A1 | |
| SCHEMBL29122680 | 0.80 | ELANE (0.48) | CNR1CNR2ROCK1ROCK2SLC2A1 | |
| SCHEMBL29122231 | 0.77 | CFD (0.42) | CNR1CNR2ROCK1ROCK2SLC2A1 | |
| SCHEMBL23218779 | 0.74 | MAPT (0.39) | CNR1CNR2MAPTSLC2A1SLC2A2 | |
| SCHEMBL29121814 | 0.72 | MAPK8 (0.42) | CNR1CNR2MAPTMAPK1 | |
| SCHEMBL29121796 | 0.72 | SLC2A1 (0.44) | CNR1CNR2ROCK1ROCK2TDO2 | |
| SCHEMBL23228990 | 0.70 | MAPK8 (0.37) | CNR1CNR2MAPT | |
| SCHEMBL29122103 | 0.69 | KDM4C (0.39) | CNR1CNR2MAPTPIK3CAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | CNR1 4787/4885CNR2 4730/4885ROCK1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.